With effectiveness beyond diabetes and obesity, Noom is leveraging Big Pharmas declaration of GLP-1s as longevity medicinewhile prescribing minimal effective dosesto normalize the treatment and supercharge its platforms outcomes
This review provides a comprehensive examination of the pathophysiology, risk factors, and strategies for managing SFSS across the pre-, intra-, and postoperative phases
Safety Concerns: Side Effects of Dual GLP-1 Therapy Both semaglutide and tirzepatide carry common gastrointestinal side effects including nausea, vomiting, diarrhea, constipation, and abdominal painespecially during dose escalation
Image credit: KaterynaBorodina/Shutterstock.com The amount of semaglutide patients receive may matter more for long-term heart health than the amount of weight they lose, according to a new retrospective study published in npj Cardiovascular Health
No more counting calendar days incorrectly because you forgot the exact timing
The northside suburbs are well served
